News & Views
Agreement to Advance Preclinical Services
Oct 22 2020
US Biotech Applied StemCell, has signed a licencing agreement with Dublin-based ERS Genomics for use of its CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, for developing its preclinical research tools, including cell and animal model generation, antibody discovery and preclinical assay services to support cell and gene product development.
“Applied StemCell has been a leading stem cell company I have followed for many years," said Eric Rhodes, CEO of ERS Genomics. “It is exciting to see their expertise in cell and animal models being combined with the power of CRISPR gene editing."
“We are extremely excited to build on the strength of our existing platform while investing our R&D in emerging technologies to drive our future growth,” added Ruby Tsai, CEO of Applied StemCell.
Financial details of the agreement were not disclosed.
More information online
In This Edition Articles - NMR for Electrolyte Design - Specialty Chromatography Detectors: Make or Buy? - Energy Efficient Autoclaves - Misconceptions and Misunderstanding Mass Spectrom...
View all digital editions
Aug 01 2021 Virtual event
Aug 02 2021 Virtual event
Aug 10 2021 Pennsylvania, PA, USA & Online
Aug 18 2021 Beijing, China
Aug 22 2021 Xi'an, China